Quick answers
- What is Droxidopa used for?
- The FDA-approved label (Northera, Lundbeck Pharmaceuticals LLC, July 1, 2019) says: “NORTHERA is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Droxidopa have a boxed warning?
- Yes. The FDA label for Northera has a boxed warning (“WARNING: SUPINE HYPERTENSION”), the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Droxidopa?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Droxidopa been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Droxidopa?
- 15 companies list prescription products of Droxidopa in the FDA NDC Directory, including CivicaScript LLC, Major Pharmaceuticals and Camber Pharmaceuticals, Inc..
What Droxidopa is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
NORTHERA is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. …
— FDA label: Northera, Lundbeck Pharmaceuticals LLC, effective July 1, 2019. Read the full label on DailyMed →
The FDA has 15 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Its heading: WARNING: SUPINE HYPERTENSION
. Read it on the full label →
14 of 15 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Capsule |
|---|---|
| Route | Oral |
| Prescription products | 45 in the FDA NDC Directory |
| Brand names | Northera |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| droxidopa 100 mg capsule | Generic | $0.4697 per capsule |
| droxidopa 200 mg capsule | Generic | $0.9861 per capsule |
| droxidopa 300 mg capsule | Generic | $1.85 per capsule |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- CivicaScript LLC3 products
- Major Pharmaceuticals3 products
- Camber Pharmaceuticals, Inc.3 products
- ScieGen Pharmaceuticals, Inc.3 products
- Aurobindo Pharma Limited3 products
- Ascend Laboratories, LLC3 products
- Lupin Pharmaceuticals, Inc.3 products
- Zydus Pharmaceuticals USA Inc.3 products
- Zydus Lifesciences Limited3 products
- Novadoz Pharmaceuticals LLC3 products
- Sun Pharmaceutical Industries, Inc.3 products
- Lundbeck Pharmaceuticals LLC3 products
- Golden State Medical Supply, Inc.3 products
- Bionpharma Inc.3 products
- Slate Run Pharmaceuticals, LLC3 products
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA203202 NORTHERA | Lundbeck Na Ltd | February 18, 2014 | 7, latest February 10, 2017 2017: Labeling · 2016: Labeling · 2015: Manufacturing (CMC) |
Generic approvals (10)
- ANDA211652Lupin Pharms · February 18, 2021
- ANDA211726Annora · February 18, 2021
- ANDA211741Msn Pharms Inc · February 18, 2021
- ANDA211818Zydus Pharms · February 18, 2021
- ANDA213911Alkem Labs Ltd · February 18, 2021
- ANDA214017Sciegen Pharms · February 18, 2021
- ANDA214384Sun Pharm · February 18, 2021
- ANDA214387Aurobindo Pharma Ltd · February 18, 2021
- ANDA213033Bionpharma · April 28, 2021
- ANDA215265Pharmazone · November 1, 2021
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Northera, Lundbeck Pharmaceuticals LLC, effective July 1, 2019; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →